Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?

被引：0
作者：
Marek Z. Wojtukiewicz
Magda Pogorzelska
Barbara Politynska
机构：
[1] Medical University of Bialystok,Department of Oncology
[2] Comprehensive Cancer Center,Department of Clinical Oncology
[3] Medical University of Bialystok,Department of Psychology and Philosophy
来源：
Cancer and Metastasis Reviews | 2022年 / 41卷
关键词：
Triple negative; Breast cancer; TNBC; Immunotherapy; Future targets;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：465 / 469
页数：4
相关论文
共 161 条
[11]  
Wardley A(2021)Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment Biomark Research 9 59-undefined
[12]  
Kaen D(2020)Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC New England Journal of Medicine 383 1328-undefined
[13]  
Andrade L(2022)Progress and prospect of immunotherapy for triple-negative breast cancer Frontiers in Oncology 12 919072-undefined
[14]  
Semiglazov V(2021)Mucin1 and Mucin16: Therapeutic targets for cancer therapy Pharmaceuticals (Basel) 14 1053-undefined
[15]  
Reinisch M(2019)Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer Oncoimmunology 8 e1674605-undefined
[16]  
Patel S(2020)Oncolytic vesicular stomatitis virus-based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8+ T-cell functionality Journal for Immunotherapy of Cancer 8 e000465-undefined
[17]  
Patre M(undefined)undefined undefined undefined undefined-undefined
[18]  
Morales L(undefined)undefined undefined undefined undefined-undefined
[19]  
Patel SL(undefined)undefined undefined undefined undefined-undefined
[20]  
Kaul M(undefined)undefined undefined undefined undefined-undefined
12345678910